title: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
authors.affiliation: Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA. mdavis@cheme.caltech.edu
authors.forename: Mark E
authors.initials: ME
authors.lastname: Davis
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Zuckerman
authors.forename: Chung Hang J
authors.initials: CH
authors.lastname: Choi
authors.forename: David
authors.initials: D
authors.lastname: Seligson
authors.forename: Anthony
authors.initials: A
authors.lastname: Tolcher
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Alabi
authors.forename: Yun
authors.initials: Y
authors.lastname: Yen
authors.forename: Jeremy D
authors.initials: JD
authors.lastname: Heidel
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
mesh_terms: D001706:Biopsy; D017321:Clinical Trials, Phase I as Topic; D004337:Drug Carriers / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D055785:Gene Knockdown Techniques / Q000379:methods*; D006801:Humans; D007275:Injections, Intravenous; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D053758:Nanoparticles / Q000008:administration & dosage / Q000032:analysis; D034622:RNA Interference / Q000187:drug effects*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D011990:Receptors, Transferrin / Q000378:metabolism; D012262:Ribonucleoside Diphosphate Reductase / Q000096:biosynthesis / Q000235:genetics
chemical_list: D004337:Drug Carriers; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D011990:Receptors, Transferrin; C093713:ribonucleotide reductase M2; D012262:Ribonucleoside Diphosphate Reductase